Back to search results

Acetazolamide for Treatment Resistant Schizophrenia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Schizophrenia · Schizo Affective Disorder

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Pittsburgh, Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Maribeth A Wesesky, BPS) · weseskyma@upmc.edu · 412-295-7017
    Satish Iyengar, Ph.D. (Sub-investigator)
    Konasale Prasad, M.D. (Sub-investigator)
    Maribeth A Wesesky, BPS (Sub-investigator)
    Ian Conner, M.D. (Sub-investigator)
    Madhavi K Ganapathiraju, Ph.D. (Sub-investigator)
    Roy KN Chengappa, M.D. (Sub-investigator)

  • St John's Medical College Hospital, Bangalore, India

    Contact: Study coordinator (Smita N Deshpande, M.D.) · smitadeshp@gmail.com · (91)- 93126-54702
    Contact: Study coordinator (Triptish Bhatia, Ph.D.) · bhatiatriptish@yahoo.co.in · (91)-11-23404363
    Ashok Mysore, M.D. (Sub-investigator)
    Anil Kakunje, M.D. (Sub-investigator)
    Contact: Principal Investigator (Smita Deshpande, M.D.)
Study leads

  • Vishwajit L Nimgaonkar, M.D., Ph.D.

    Principal Investigator

    University of Pittsburgh

View source on ClinicalTrials.gov(opens in a new tab)